LON:HIK Hikma Pharmaceuticals (HIK) Share Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free HIK Stock Alerts GBX 1,918.50 +38.00 (+2.02%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range 1,887.50▼ 1,937.5050-Day Range 1,841▼ 2,08352-Week Range 1,614.50▼ 2,222Volume332,600 shsAverage Volume443,218 shsMarket Capitalization£4.26 billionP/E Ratio2,863.43Dividend Yield2.97%Price TargetGBX 2,018.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Get Hikma Pharmaceuticals alerts: Email Address Hikma Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside5.2% UpsideGBX 2,018.75 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-2.61Upright™ Environmental ScoreNews Sentiment0.80Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.60 out of 5 stars 1.3 Analyst's Opinion Consensus RatingHikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 2,018.75, Hikma Pharmaceuticals has a forecasted upside of 5.2% from its current price of GBX 1,918.50.Amount of Analyst CoverageHikma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HIK. Previous Next 0.8 Dividend Strength Dividend YieldHikma Pharmaceuticals pays a meaningful dividend of 2.93%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 8,507.46%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHikma Pharmaceuticals has received a 48.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Abiraterone", "Cancer medication (L01)", "Isosorbide dinitrate", and "HIV medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Hikma Pharmaceuticals is -2.61. Previous Next 2.7 News and Social Media Coverage News SentimentHikma Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders30.72% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.25% of the stock of Hikma Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 2,863.43, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 147.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 2,863.43, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 275.57.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Hikma Pharmaceuticals Stock (LON:HIK)Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.Read More HIK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIK Stock News HeadlinesMarch 23, 2024 | americanbankingnews.comHikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarch 22, 2024 | finance.yahoo.comGlobal Lidocaine Hydrochloride Market Report 2024, by Dosage Form, Application, Distribution Channel and RegionMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 22, 2024 | americanbankingnews.comHikma Pharmaceuticals (LON:HIK) Share Price Crosses Above 200 Day Moving Average of $1,913.46March 21, 2024 | finance.yahoo.comLidocaine Hydrochloride Market Forecasted to Reach USD 1.56 Billion by 2034 with Robust Growth in Asia Pacific RegionMarch 17, 2024 | msn.comBig pharma shakeup in Morocco as Sanofi sells business to HikmaMarch 15, 2024 | finanznachrichten.deHyloris Pharmaceuticals SA: Hyloris Reports Full Year Results for 2023 & Provides Business OutlookMarch 14, 2024 | uk.finance.yahoo.comHyloris Reports Full Year Results for 2023 & Provides Business OutlookMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 13, 2024 | morningstar.comFTSE 100 Closes Up 0.12% Ahead of U.K. Jobs DataMarch 13, 2024 | markets.businessinsider.comBioHarvest Sciences Announces New Strategic Hires for CDMO Services Business UnitMarch 4, 2024 | msn.comThe 9th edition of the GCC Regulatory Affairs Pharma Summit is set to convene in Dubai in 2024, marking a significant gathering of over 400 professionals, including regional ...February 27, 2024 | finanznachrichten.deHyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In CanadaFebruary 27, 2024 | finance.yahoo.comHyloris Announces Launch of Maxigesic® IV in the U.S. and approval In CanadaFebruary 22, 2024 | thetimes.co.ukHikma beats profit estimates thanks to narcolepsy drugFebruary 22, 2024 | msn.comFTSE 100 Live 22 February: Lloyds results, shares start higher after Nvidia beats expectationsFebruary 22, 2024 | lse.co.ukTOP NEWS: Hikma boosts dividend after year of "significant progress"February 22, 2024 | marketwatch.comHikma Pharmaceutical FY EPS 85cFebruary 21, 2024 | finance.yahoo.comHikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityFebruary 8, 2024 | msn.comHigher-dose naloxone spray didn't save more lives, researchers findFebruary 8, 2024 | finance.yahoo.comHigh-dose opioid reversal spray no better than lower dose in field, US study findsFebruary 7, 2024 | msn.comNZ-developed intravenous product launches in United StatesFebruary 5, 2024 | news.yahoo.comMass. AG announces opioid settlements with two companies. State to get $8 million.February 5, 2024 | msn.comVirginia expected to receive $2M+ from opioid manufacturer lawsuitFebruary 2, 2024 | msn.comAd agency tied to Purdue Pharma settles opioid claims for $350 millionFebruary 1, 2024 | msn.comOregon Supreme Court rules lawmakers cannot seek reelection after Senate boycottFebruary 1, 2024 | msn.comOpioid settlements announced with two companiesSee More Headlines Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 5/3 Dividend3/21/2024Today3/28/2024Dividend Payable5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:HIK CUSIPN/A CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees9,100Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,018.75 High Stock Price TargetGBX 2,150 Low Stock Price TargetGBX 1,800 Potential Upside/Downside+5.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.67 Trailing P/E Ratio2,863.43 Forward P/E Ratio12.63 P/E Growth2.38Net Income£190 million Net Margins6.61% Pretax MarginN/A Return on Equity8.81% Return on Assets8.52% Debt Debt-to-Equity Ratio53.92 Current Ratio1.57 Quick Ratio1.27 Sales & Book Value Annual Sales£2.88 billion Price / Sales1.48 Cash FlowGBX 230.07 per share Price / Cash Flow8.34 Book ValueGBX 996 per share Price / Book1.93Miscellaneous Outstanding Shares221,880,000Free FloatN/AMarket Cap£4.26 billion OptionableNot Optionable Beta0.45 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Comp: $2.33MMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Comp: $1.53MMr. Riad MishlawiCEO & DirectorMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Mr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive VP of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive VP of Strategic Planning & Global AffairsMr. Brian HoffmannPresident of GenericsMr. Samuel ParkGlobal Head of Intellectual Property (IP) & General Counsel for USMore ExecutivesKey CompetitorsIndiviorLON:INDVHUTCHMEDLON:HCMDechra PharmaceuticalsLON:DPHMediclinic InternationalLON:MDCBTGLON:BTGView All CompetitorsInsidersDouglas HurtBought 1,500 shares on 6/6/2023Total: £2.73 M ($1,820.00/share)View All Insider Transactions HIK Stock Analysis - Frequently Asked Questions Should I buy or sell Hikma Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIK shares. View HIK analyst ratings or view top-rated stocks. What is Hikma Pharmaceuticals' stock price target for 2024? 6 brokerages have issued 12 month target prices for Hikma Pharmaceuticals' stock. Their HIK share price targets range from GBX 1,800 to GBX 2,150. On average, they predict the company's share price to reach GBX 2,018.75 in the next twelve months. This suggests a possible upside of 5.2% from the stock's current price. View analysts price targets for HIK or view top-rated stocks among Wall Street analysts. How have HIK shares performed in 2024? Hikma Pharmaceuticals' stock was trading at GBX 1,789 at the start of the year. Since then, HIK stock has increased by 7.2% and is now trading at GBX 1,918.50. View the best growth stocks for 2024 here. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals declared a dividend on Thursday, February 22nd. Stockholders of record on Thursday, March 21st will be given a dividend of GBX 0.47 per share on Friday, May 3rd. This represents a yield of 1.86%. The ex-dividend date of this dividend is Thursday, March 21st. This is a boost from the stock's previous dividend of GBX 0.25. The official announcement can be seen at this link. Read our dividend analysis for HIK. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 57 per share and currently has a dividend yield of 2.93%. The dividend payout ratio is 8,507.46%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for HIK. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC). How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:HIK) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.